Saxenda Cost in Utah (2026): Prices, Insurance, and Savings Options

What Saxenda Costs at Utah Retail Pharmacies

The standard retail price for a 30-day supply of Saxenda at Utah pharmacies is $1,349, matching the Novo Nordisk wholesale acquisition cost. Pharmacies in Salt Lake City, Provo, Ogden, and St. George report prices within a narrow band of this figure, with minimal variation between chains.

This pricing reflects five pre-filled pens per carton, each containing 18 mg of liraglutide. At the maintenance dose of 3 mg per day, one carton lasts exactly 30 days. During the initial 4-week dose-escalation period (starting at 0.6 mg daily and increasing weekly by 0.6 mg increments), patients use less medication per day, so the first carton may stretch slightly longer [1].

Pharmacy benefit managers negotiate rebates that sit behind the scenes. The rebate structure means the price a patient actually pays depends almost entirely on their insurance formulary tier. A patient with no coverage and no discount card faces the full $1,349. That number has held steady since late 2024, when Novo Nordisk last adjusted the wholesale acquisition cost.

Coupon aggregator platforms (GoodRx, RxSaver, SingleCare) sometimes list Utah prices between $1,100 and $1,300 at select independent pharmacies, but availability fluctuates. These platforms do not stack with insurance copay cards.

Utah Medicaid and Saxenda: Not Covered

Utah Medicaid does not cover Saxenda for chronic weight management. This exclusion applies to both traditional Medicaid and the expanded Medicaid population that Utah enrolled following the 2018 ballot initiative (Proposition 3) and subsequent legislative implementation.

The exclusion is consistent with how most state Medicaid programs treat GLP-1 receptor agonists prescribed solely for obesity. The Centers for Medicare & Medicaid Services allows states to exclude weight-loss drugs from Medicaid formularies under the Social Security Act, and Utah exercises that option [2]. Liraglutide at the lower 1.8 mg dose (branded as Victoza) is covered by Utah Medicaid for type 2 diabetes, but the 3 mg weight-management formulation is not.

For Utah Medicaid beneficiaries seeking pharmacotherapy for obesity, the practical alternatives are older, generic medications. Phentermine (a Schedule IV stimulant) and phentermine-topiramate (Qsymia) carry lower price points, though neither is a GLP-1 receptor agonist. Orlistat (Xenical, or over-the-counter Alli) is another formulary option in some managed Medicaid plans. These drugs produce more modest weight loss than liraglutide 3 mg. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated 8.0% mean body weight reduction with liraglutide 3 mg versus 2.6% with placebo at 56 weeks [1], a magnitude that phentermine monotherapy does not consistently match.

Patients on Utah Medicaid who have a concurrent diagnosis of type 2 diabetes should discuss Victoza (liraglutide 1.8 mg) or semaglutide 1 mg (Ozempic) with their prescriber, as these may be covered under the diabetes benefit.

Private Insurance Coverage in Utah

Private insurance plans in Utah vary in their Saxenda coverage. Large employers and marketplace plans administered by SelectHealth, Regence BlueCross BlueShield, Molina, and University of Utah Health Plans each maintain independent formulary decisions, so no blanket statement applies across the state.

Common patterns emerge across Utah's commercial market. Most plans that do cover Saxenda require prior authorization. The typical prior authorization criteria mirror the FDA-approved indication: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [3]. Many plans also require documentation of a failed lifestyle intervention (diet and exercise counseling for 3 to 6 months).

SelectHealth, the largest Utah-based insurer and an Intermountain Health affiliate, has historically placed Saxenda on a specialty tier with step-therapy requirements. Patients may need to try and fail a lower-cost weight-management medication before Saxenda is approved.

When coverage is granted, copays range from $30 to $150 per month depending on the plan's specialty tier structure. High-deductible health plans paired with HSAs leave the patient responsible for the full $1,349 until the deductible is met, at which point coinsurance (often 20% to 40%) applies.

A practical first step: call the number on the back of your insurance card and ask specifically whether liraglutide 3 mg (NDC 0169-4060-12) is on formulary and what the prior authorization requirements are.

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Saxenda that can reduce out-of-pocket costs to as low as $25 per fill for eligible patients. The card is available to commercially insured patients whose plans cover Saxenda but impose a copay or coinsurance.

Eligibility rules exclude patients covered by any federal or state healthcare program. That means Medicare Part D, Medicaid, Tricare, and VA benefits disqualify a patient. The card also has an annual maximum benefit (historically around $200 per fill, up to a yearly cap), which means patients with very high coinsurance may still face meaningful costs even with the card active.

To use the card in Utah, patients present it as a secondary payer at their pharmacy. The pharmacist runs the primary insurance first, then applies the savings card to the remaining copay balance. Processing is electronic and uses standard BIN/PCN/Group identifiers printed on the card. Most Utah chain pharmacies (Walgreens, CVS, Smith's, Harmons) are familiar with the workflow.

The card does not apply to compounded liraglutide. It is valid only for the branded Saxenda product dispensed from Novo Nordisk's supply chain.

Compounded Liraglutide 3 mg in Utah

Licensed 503A compounding pharmacies in Utah can legally prepare liraglutide 3 mg for individual patients with valid prescriptions. This pathway exists under the Federal Food, Drug, and Cosmetic Act Section 503A, which permits patient-specific compounding by state-licensed pharmacies when a prescriber-patient relationship exists [4].

The legality in Utah is straightforward. The Utah Division of Occupational and Professional Licensing (DOPL) regulates pharmacy compounding under Utah Code Title 58, Chapter 17b. A 503A pharmacy operating in Utah, or a 503A pharmacy in another state shipping into Utah under applicable interstate rules, may compound liraglutide provided it is not an essentially copy of a commercially available product for a specific patient with a medical need that the commercial product does not meet (for example, a patient who needs a dose not available in the pre-filled pen format, or who has a documented allergy to an inactive ingredient in Saxenda).

Pricing from 503A compounding pharmacies varies but is typically a fraction of the branded cost. Some telehealth platforms that partner with compounding pharmacies advertise liraglutide programs starting around $150 to $350 per month, though prices depend on dosage, pharmacy, and whether consultations are bundled.

Patients considering compounded liraglutide should verify two things. First, confirm the pharmacy holds a valid Utah state license or is registered to ship into Utah. Second, ask whether the pharmacy participates in voluntary accreditation through the Pharmacy Compounding Accreditation Board (PCAB) or holds NABP accreditation, as these signal higher quality-control standards.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine and an investigator on the SCALE trials, has noted: "The efficacy of liraglutide depends on the molecule reaching the receptor at the right concentration. For compounded versions, patients should have confidence in the pharmacy's quality-assurance processes" [5].

Telehealth Access to Saxenda in Utah

Utah allows prescribers to write Saxenda prescriptions via telehealth. The state's telehealth parity law (Utah Code 26-60) and subsequent updates through 2025 permit the establishment of a provider-patient relationship through synchronous audio-video encounters, which satisfies the prescribing requirement for liraglutide [6].

Several national telehealth platforms operate in Utah and offer Saxenda or compounded liraglutide programs. These platforms typically charge a consultation fee ($50 to $199 for an initial visit) and then either send the prescription to a retail pharmacy or fulfill through a partnered compounding pharmacy.

For patients in rural Utah counties (Daggett, Wayne, Piute, Garfield) where endocrinology or obesity-medicine specialists are scarce, telehealth is often the most practical route to a prescriber experienced with GLP-1 agonist titration and monitoring.

The prescribing provider must hold an active Utah medical license or be practicing under a valid interstate compact. The APRN Compact and the Interstate Medical Licensure Compact both apply in Utah, broadening the pool of available prescribers.

How Saxenda Compares to Other GLP-1 Options on Price

Utah patients weighing Saxenda against other GLP-1 receptor agonists should consider both efficacy and cost. Semaglutide 2.4 mg (Wegovy), the other FDA-approved GLP-1 for chronic weight management, has a list price of approximately $1,349 per month as well, but produces greater weight loss. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss with semaglutide 2.4 mg versus 2.4% with placebo at 68 weeks [7]. By comparison, the SCALE trial showed 8.0% with liraglutide 3 mg versus 2.6% with placebo at 56 weeks [1].

Tirzepatide (Zepbound), a dual GIP/GLP-1 receptor agonist, carries a list price of approximately $1,059 per month and produced up to 22.5% weight loss in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose [8]. Tirzepatide is dosed weekly rather than daily, which some patients prefer.

The daily injection frequency of Saxenda (versus weekly for Wegovy and Zepbound) is a practical consideration. Some patients find daily dosing easier to titrate if side effects arise, because the drug clears faster (half-life of approximately 13 hours versus 7 days for semaglutide). Others prefer the convenience of once-weekly administration.

From a pure cost-effectiveness standpoint, the American Gastroenterological Association's 2024 clinical practice guideline on pharmacotherapy for obesity recommends semaglutide 2.4 mg and tirzepatide as first-line agents over liraglutide 3 mg, based on superior weight-loss efficacy at comparable or lower price points [9].

Step-by-Step: Getting the Lowest Price in Utah

A practical approach for Utah residents seeking Saxenda at the lowest cost involves working through a specific sequence.

First, check insurance formulary status. Call your plan's pharmacy benefits number and request the formulary tier and prior authorization criteria for liraglutide 3 mg (NDC 0169-4060-12). If covered, ask about the Novo Nordisk savings card stacking on top of your copay.

Second, if uninsured or if the plan excludes Saxenda, request a GoodRx or RxSaver price check at three or four Utah pharmacies. Costco pharmacies (you do not need a membership to use the pharmacy) often post the lowest retail cash prices for specialty injectables.

Third, explore compounded liraglutide. Ask your prescriber whether a compounded formulation is clinically appropriate. If so, verify the compounding pharmacy's licensure through the Utah DOPL license lookup portal.

Fourth, consider whether semaglutide or tirzepatide might offer better value. If your insurer covers Wegovy or Zepbound with a lower copay than Saxenda, the switch may save money and produce greater weight loss.

Fifth, investigate patient assistance. Novo Nordisk's Patient Assistance Program (PAP) provides free Saxenda to qualifying patients with household income at or below 400% of the federal poverty level who lack prescription drug coverage.

Safety Monitoring and Ongoing Costs

Beyond the drug itself, Utah patients should budget for the clinical monitoring that accompanies liraglutide therapy. The FDA label for Saxenda includes a boxed warning regarding the risk of thyroid C-cell tumors, based on rodent studies. Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3].

Routine follow-up typically includes quarterly office visits (or telehealth check-ins) and periodic lab work. A basic metabolic panel and lipid panel every 6 to 12 months are standard. For patients with prediabetes, the SCALE Obesity and Prediabetes trial found that liraglutide 3 mg reduced the time to onset of type 2 diabetes by 2.7 years compared to placebo over 3 years of treatment, with an 80% reduction in diabetes diagnosis during the treatment period [1]. Hemoglobin A1c monitoring is reasonable in this population.

Heart rate increases of 2 to 3 beats per minute have been observed with liraglutide 3 mg in clinical trials [3]. Patients with resting tachycardia or arrhythmia history should discuss this with their prescriber. The LEADER cardiovascular outcomes trial, conducted at the 1.8 mg diabetes dose, showed a 13% reduction in the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (HR 0.87 to 95% CI 0.78 to 0.97, P=0.01) [10]. The 3 mg weight-management dose has not been studied in a dedicated cardiovascular outcomes trial, but the mechanism is identical.

Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) are the most common reason for discontinuation. In SCALE, 9.8% of liraglutide patients discontinued due to adverse events versus 4.3% on placebo [1]. The 4-week titration schedule exists specifically to mitigate GI intolerance. Patients who rush the titration experience more nausea.

The maintenance dose of 3 mg daily must be reached by week 5 for the full weight-loss benefit. If a patient cannot tolerate 3 mg after appropriate titration, the FDA label states the drug should be discontinued rather than maintained at a subtherapeutic dose [3].